Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lambert, A.
Right arrow Articles by Robertson, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert, A.
Right arrow Articles by Robertson, W. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Molecular Human Reproduction, Vol 4, 619-629, Copyright © 1998 by Oxford University Press

REVIEW, ACADEMIC

Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction

A Lambert, JA Talbot, CJ Anobile and WR Robertson
Department of Medicine, Hope Hospital, Salford, UK.

The extensive heterogeneity of the gonadotrophin hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH), is due primarily to the heterogeneous nature of their carbohydrate side- chains, in particular sialic acid residues. In this review, we discuss the role of carbohydrate chains in receptor binding and activation, biological activity, and metabolic half-life. The synthesis and secretion of the various glycoforms of both FSH and LH appear to be under endocrine control with gonadotrophin-releasing hormone (GnRH), oestradiol and testosterone playing important roles. Evidence for different glycoforms having variable biopotency or different encoded functions is increasing, and the production and secretion of more or less acidic gonadotrophin species in different physiological states may represent an important mechanism whereby the pituitary regulates gonadal cell and organ function. This has potential importance for the development of new pharmaceutical reagents and new therapeutic regimens in assisted reproduction. It is envisaged that the use of existing and new forms of FSH/LH will allow patients to be treated in a more controlled and physiological manner, with treatment regimens individualized to the needs of the patient.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
V. J. Grant and L. W. Chamley
Sex-Sorted Sperm and Fertility: An Alternative View
Biol Reprod, February 1, 2007; 76(2): 184 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Zarinan, A. Olivares, D. Soderlund, J.P. Mendez, and A. Ulloa-Aguirre
Changes in the biological:immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory and luteal phases of the human menstrual cycle
Hum. Reprod., August 1, 2001; 16(8): 1611 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Ulloa-Aguirre, C. Timossi, and J.P. Mendez
Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans?: I. Gondatrophins are synthesized and released in multiple molecular forms. A matter of fact
Hum. Reprod., April 1, 2001; 16(4): 599 - 604.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Olivares, M. Cardenas, C. Timossi, T. Zarinan, V. Diaz-Sanchez, and A. Ulloa-Aguirre
Reactivity of different LH and FSH standards and preparations in the World Health Organization matched reagents for enzyme-linked immunoassays of gonadotrophins
Hum. Reprod., November 1, 2000; 15(11): 2285 - 2291.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. Horsman, J.A. Talbot, J.D. McLoughlin, A. Lambert, and W.R. Robertson
A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon
Hum. Reprod., September 1, 2000; 15(9): 1898 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. H.M. Hoomans, A. N. Andersen, A. Loft, R. A. Leerentveld, A. A. van Kamp, and H. Zech
A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon(R)) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP(R)) in a fixed-dose regimen in women undergoing ovarian stimulation
Hum. Reprod., October 1, 1999; 14(10): 2442 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
C. Y. Andersen, L. Leonardsen, A. Ulloa-Aguirre, J. Barrios-De-Tomasi, L. Moore, and A.G. Byskov
FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms
Mol. Hum. Reprod., August 1, 1999; 5(8): 726 - 731.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. H. Balen, C. J. Hayden, and A. J. Rutherford
Clinical efficacy of recombinant gonadotrophins
Hum. Reprod., June 1, 1999; 14(6): 1411 - 1417.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
M. D'Antonio, F. Borrelli, A. Datola, R. Bucci, M. Mascia, P. Polletta, D. Piscitelli, and R. Papoian
Biological characterization of recombinant human follicle stimulating hormone isoforms
Hum. Reprod., May 1, 1999; 14(5): 1160 - 1167.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.